Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Abstracts IgAN

Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial

View
Publications IgAN

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

View
Publications IgAN

Clinicopathological Characteristics of Adult IgA Nephropathy in the United States

View
Publications IgAN

Impact of Proteinuria and Kidney Function Decline on Health Care Costs and Resource Utilization in Adults With IgA Nephropathy in the United States: A Retrospective Analysis

View
Medical Information IgAN

SPARTAN (Phase 2 Study): Sparsentan as First-Line Therapy in the Treatment of IgA Nephropathy

Learn more
Medical Information IgAN

SPARTACUS (Phase 2 Study): Sparsentan in Combination With SGLT2 Inhibitors Study Design

Learn more
Medical Information FSGS

EPPIK (Phase 2 Study): Treatment in Pediatric Patients With Proteinuric Glomerular Diseases

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – PROTECT (Phase 3 Study): Study Design & Results

Learn more
Medical Information IgAN

Long-Term Outcomes in IgA Nephropathy Published in the CJASN

Learn more
Medical Information IgAN

UK National Registry of Rare Kidney Disease: Long-Term Outcomes in the IgA Nephropathy Cohort

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – Baseline Characteristics of Asian vs Non-Asian Patients in the PROTECT Study

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Hyperkalemia

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Acute Kidney Injury

Learn more